Generic Sweden の収益と比較して、Jonas Jegerborn の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	SEK 23m
Mar 31 2024	n/a	n/a	SEK 23m
Dec 31 2023	SEK 3m	n/a	SEK 23m
Sep 30 2023	n/a	n/a	SEK 24m
Jun 30 2023	n/a	n/a	SEK 23m
Mar 31 2023	n/a	n/a	SEK 21m
Dec 31 2022	SEK 3m	n/a	SEK 20m
Sep 30 2022	n/a	n/a	SEK 19m
Jun 30 2022	n/a	n/a	SEK 18m
Mar 31 2022	n/a	n/a	SEK 19m
Dec 31 2021	SEK 3m	n/a	SEK 18m
Sep 30 2021	n/a	n/a	SEK 17m
Jun 30 2021	n/a	n/a	SEK 15m
Mar 31 2021	n/a	n/a	SEK 13m
Dec 31 2020	SEK 3m	n/a	SEK 11m
Sep 30 2020	n/a	n/a	SEK 10m
Jun 30 2020	n/a	n/a	SEK 10m
Mar 31 2020	n/a	n/a	SEK 9m
Dec 31 2019	SEK 2m	SEK 1m	SEK 9m

報酬と市場: Jonasの総報酬 ($USD 283.81K ) は、 Swedish市場 ($USD 279.51K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jonasの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jonas Jegerborn (52 yo)

no data

在職期間

SEK 2,888,000

報酬

Mr. Jonas Jegerborn serves as the Chief Executive Officer and President at Generic Sweden AB.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jonas Jegerborn	President & CEO	no data	SEK 2.89m	1.47% SEK 8.1m
Susanne Lundin	Chief Financial Officer	3.6yrs	データなし	データなし
Magnus Rasmusson	Chief Technology Officer	4.8yrs	データなし	データなし
Madelene Persson	Marketing Manager	5.7yrs	データなし	データなし

4.8yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: GENIの経営陣は経験豊富であると考えられます ( 4.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Bengt-Arne Molin	Independent Director	4.3yrs	SEK 100.00k	0.055% SEK 300.8k
Hans Krantz	Chairman of the Board	14.8yrs	SEK 200.00k	21.82% SEK 119.9m
Stefan Widen	Independent Director	10.3yrs	SEK 100.00k	データなし
Johanna Berlinde	Independent Director	1.3yrs	SEK 100.00k	データなし
Erik Ivarsson	Director	2.3yrs	SEK 100.00k	0.11% SEK 625.8k

4.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: GENIの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

Generic Sweden マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Less than half of directors are independent

Owner & Member of the board recently sold kr3.5m worth of stock

Owner & Member of the board recently sold kr3.1m worth of stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Recent updates

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 24% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued

First quarter 2024 earnings: Revenues exceed analyst expectations

Now 23% undervalued

Upcoming dividend of kr1.50 per share

Now 23% undervalued after recent price drop

Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 16%

Now 25% undervalued

Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Investor sentiment improves as stock rises 16%

Now 22% undervalued

Third quarter 2023 earnings: Revenues exceed analyst expectations

Investor sentiment improves as stock rises 21%

Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

New major risk - Earnings quality

Investor sentiment improves as stock rises 17%

Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Upcoming dividend of kr1.25 per share at 2.9% yield

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 21%

Full year 2022 earnings: EPS exceeds analyst expectations

Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

Now 21% undervalued

Now 21% undervalued

Third quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues miss analyst expectations

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

First quarter 2022 earnings: Revenues miss analyst expectations

Upcoming dividend of kr1.00 per share

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Less than half of directors are independent

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Investor sentiment improved over the past week

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.5m worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Owner & Member of the board recently sold kr3.1m worth of stock

Third quarter 2021 earnings released

With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Investor sentiment improved over the past week

Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Owner & Member of the board recently sold kr1.4m worth of stock

Owner & Member of the board recently sold kr1.3m worth of stock

Investor sentiment improved over the past week

First quarter 2021 earnings released

Upcoming dividend of kr0.80 per share

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

マネジメント基準チェック /44